A recombinant human interleukin-1 beta protects adriamycin-induced toxicity. Adriamycin cardiotoxicity and interleukin-1

Biotherapy. 1993;7(2):137-43. doi: 10.1007/BF01877737.

Abstract

Pretreatment with recombinant human interleukin-1 beta (IL-1) protected normal BALB/c mice from the lethal effect adriamycin (ADM) of related to dose and frequency of administration. Posttreatment with IL-1 failed to protect. Neutrophil and platelet counts after the administration of ADM (16 mg/kg) did not differ between the group with and that without IL-1 pretreatment, whereas lipid peroxide levels in the heart were reduced in the group pretreated with IL-1. It appears that the chemoprotection mechanism of IL-1 lies in the prevention of cardiotoxicity due to ADM-induced free radicals.

MeSH terms

  • Animals
  • Dose-Response Relationship, Drug
  • Doxorubicin / toxicity*
  • Heart / drug effects*
  • Interleukin-1 / pharmacology*
  • Leukocyte Count / drug effects
  • Lipid Peroxides / analysis
  • Male
  • Mice
  • Mice, Inbred BALB C
  • Neoplasms, Experimental / drug therapy
  • Recombinant Proteins / pharmacology
  • Superoxide Dismutase / biosynthesis

Substances

  • Interleukin-1
  • Lipid Peroxides
  • Recombinant Proteins
  • Doxorubicin
  • Superoxide Dismutase